Skip to main navigation

About Us
Programs
Join Us
Investors
Contact Us

Press Releases

Investors & Media

Overview
Press Releases
Events & Presentations
Financials
Stock Information
Analyst Coverage
Governance
Contact & FAQs

Stockholder Tools

Print Page
RSS Feeds
Email Alerts
Contact Us

Year

March 29, 2023

Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights

March 2, 2023

Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference

January 23, 2023

Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

November 17, 2022

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

November 14, 2022

Aerovate Therapeutics Announces Third Quarter 2022 Financial Results

October 18, 2022

Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022

August 15, 2022

Aerovate Therapeutics Announces Second Quarter 2022 Financial Results

June 2, 2022

Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference

May 16, 2022

Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

May 16, 2022

Aerovate Therapeutics Announces First Quarter 2022 Financial Results

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 21

Investors & Media

Overview
Press Releases
Events & Presentations
Financials
Stock Information
Analyst Coverage
Governance
Contact & FAQs

Stockholder Tools

Print Page
RSS Feeds
Email Alerts
Contact Us

About Us
Programs
Join Us
Investors
Contact Us

© 2023 Aerovate Therapeutics, Inc. All Rights Reserved. | Privacy Policy | Terms of Use